Carmen Diez

NUVISAN ICB GmbH is a Berlin-based site of the NUVISAN group, an integrated contract research organization (CRO) covering the full R&D value chain – from early discovery through preclinical development to clinical trial support. Glimpse of the Berlin Discovery Hub: We offer high-throughput screening of a proprietary 2.4M small‑molecule library, iPSC and primary cell models for translational research in oncology, CNS and women’s health, as well as biomarker discovery and multi‑omics including single‑cell, spatial and proteomics technologies. Our capabilities further include medicinal chemistry with high‑pressure reactions and chiral SFC purification, plus PK/PD and in vivo pharmacology in validated disease models. NUVISAN combines decades of pharma heritage with agile biotech culture to accelerate projects from target to patient.